Contact Information

Theodore Lowe, Ap #867-859
Sit Rd, Azusa New York

We Are Available 24/ 7. Call Now.

Gamida Cell’s Bone Marrow Transplant Cuts Treatment Time in
Phase III

A rapid-acting bone marrow transplant developed by
the Israeli biotech Gamida Cell was engrafted in blood cancer
patients 10 days faster than standard umbilical cord blood
transplants in a phase III trial.

The
trial
recruited 125 blood cancer patients in more than 50
clinical centers globally. One group received a standard transplant
of donor umbilical cord blood cells and another group received
Gamida’s treatment omidubicel, which consists of umbilical cord
blood cells that are expanded and cultured in the lab.

According to the trial results, omidubicel established itself in
the patients and started making healthy new immune cells after
around 12 days, measured by counting cells called neutrophils in
the blood. This was significantly faster than the 22 days it took
in patients given a regular umbilical cord blood transplant.

Blood cancer patients often receive stem cell transplants to
replace bone marrow cells that are damaged by chemotherapy or
radiation therapy. Donor stem cell transplants can come from adult
bone marrow cells, stem cells in the blood, or umbilical cord blood
stem cells.

A common problem with bone marrow transplants is compatibility,
where the donor’s cells could fail to engraft or even attack the
recipient if the cell types don’t match properly. This problem is

less common in umbilical cord blood transplants
than other
sources, but this type of transplant also provides a lower dose of
stem cells, which can delay the engraftment process.

To solve this issue, Gamida Cell’s treatment is designed to
take donor umbilical cord cells and boost their stem cell count in
the lab prior to administering the treatment to patients.

“These results have the potential to substantially move the
field forward and represent an important step toward making stem
cell transplantation more accessible and more successful for
patients with lethal blood cancers,
â€
stated
Mitchell Horwitz, Principal Investigator and Professor
of Medicine at the Duke Cancer Institute, USA. 

“Shortening the time to engraftment is clinically
meaningful, as it can reduce a patient’s time in the hospital and
decrease the likelihood of infection.
â€

The company aims to apply for FDA approval in late 2020, with a
potential commercial launch in 2021. According to a conference call
today, Gamida Cell had completed its phase III enrollment in
December. This meant that the trial was luckily unaffected by the
onset of the Covid-19 pandemic, which has delayed
clinical trials
for many companies worldwide.

Image from Shutterstock

The post Gamida
Cell’s Bone Marrow Transplant Cuts Treatment Time in Phase
III
appeared first on Labiotech.eu.

A rapid-acting bone marrow transplant developed by
the Israeli biotech Gamida Cell was engrafted in blood cancer
patients 10 days faster than standard umbilical cord blood
transplants in a phase III trial.

The
trial
recruited 125 blood cancer patients in more than 50
clinical centers globally. One group received a standard transplant
of donor umbilical cord blood cells and another group received
Gamida’s treatment omidubicel, which consists of umbilical cord
blood cells that are expanded and cultured in the lab.

According to the trial results, omidubicel established itself in
the patients and started making healthy new immune cells after
around 12 days, measured by counting cells called neutrophils in
the blood. This was significantly faster than the 22 days it took
in patients given a regular umbilical cord blood transplant.

Blood cancer patients often receive stem cell transplants to
replace bone marrow cells that are damaged by chemotherapy or
radiation therapy. Donor stem cell transplants can come from adult
bone marrow cells, stem cells in the blood, or umbilical cord blood
stem cells.

A common problem with bone marrow transplants is compatibility,
where the donor’s cells could fail to engraft or even attack the
recipient if the cell types don’t match properly. This problem is

less common in umbilical cord blood transplants
than other
sources, but this type of transplant also provides a lower dose of
stem cells, which can delay the engraftment process.

To solve this issue, Gamida Cell’s treatment is designed to
take donor umbilical cord cells and boost their stem cell count in
the lab prior to administering the treatment to patients.

“These results have the potential to substantially move the
field forward and represent an important step toward making stem
cell transplantation more accessible and more successful for
patients with lethal blood cancers,
â€
stated
Mitchell Horwitz, Principal Investigator and Professor
of Medicine at the Duke Cancer Institute, USA. 

“Shortening the time to engraftment is clinically
meaningful, as it can reduce a patient’s time in the hospital and
decrease the likelihood of infection.
â€

The company aims to apply for FDA approval in late 2020, with a
potential commercial launch in 2021. According to a conference call
today, Gamida Cell had completed its phase III enrollment in
December. This meant that the trial was luckily unaffected by the
onset of the Covid-19 pandemic, which has delayed
clinical trials
for many companies worldwide.

Image from Shutterstock

The post Gamida
Cell’s Bone Marrow Transplant Cuts Treatment Time in Phase
III
appeared first on Labiotech.eu.

Share:

administrator